MedTrace Logo

A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib

NCT05924152 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-03-13

No results posted yet for this study

Summary

A Phase 1, Open-label, One-sequence Crossover Study to Investigate the Effect of a Breast Cancer Resistance Protein Inhibitor on the Single-dose Pharmacokinetics of Adagrasib in Healthy Adult Subjects

Conditions

  • Healthy Adults

Interventions

DRUG

Adagrasib

Adagrasib

DRUG

Eltrombopag + adagrasib

Eltrombopag + adagrasib

Sponsors & Collaborators

  • Mirati Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-29
Primary Completion
2023-08-09
Completion
2023-08-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05924152 on ClinicalTrials.gov